Viral vector vaccine characterization services including stability and aggregation testing from Intertek's Class I and Class II Sample Handling Facility
Recombinant viruses can be utilised as tools in the development of vaccines. Acting as a vector, they deliver an immunogenic protein from an infectious agent in order to enhance the immune response in the subject, or as in some cases, they are used where giving the actual agent as a vaccine would cause disease.
Viral Vector Vaccine Stability and Aggregation Testing
A common problem in the management of viral material is the tendency for aggregation and particle formation upon extended storage. Analytical techniques are required to study the propensity of solutions to form aggregates and to allow the investigation of the conditions encountered during manufacture and storage.
Our teams of specialists apply techniques such as size exclusion chromatography with multi-angle laser light scattering (SEC-MALLS), also known as gel-permeation chromatography (GPC), and Dynamic Light Scattering (DLS) to study aggregation states of live viral products as part of stability trials.
Our laboratories have supported vaccine developers and manufacturers over the last 20 years through provision of advanced characterisation programs. Our experts have worked on multiple studies involving these types of virus products; Adenovirus, Adeno-Associated Virus (AAV) and Lentivirus. With specialist laboratory facilities, we can handle Class I and Class II Biological Agents, as stated within the European Community Directive - Classification of Infectious Biological Agents by Risk Group (2000/54EC). The facility has been designed to handle recombinant genomic materials for the purposes of research. Bringing quality and safety to life, we offer Total Quality Assurance expertise to help you to meet and exceed quality, safety and regulatory standards.
Viral Characterization Capabilities:
Need help or have a question?